BetterLife Pharma Inc. announced that it has advanced in its IND-enabling studies for BETR-001, a non-hallucinogenic derivative of LSD (lysergic acid diethylamide). The IND-enabling metabolism and genotoxicity GLP studies have been initiated. BetterLife has had its BETR-001 pre-IND meeting with the FDA, and projects to file the BETR-001 IND by end of 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.09 USD | -0.39% | +1.24% | +87.50% |
May. 29 | BetterLife Pharma Inc. Reports Earnings Results for the Full Year Ended January 31, 2024 | CI |
May. 14 | BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001 | CI |
1st Jan change | Capi. | |
---|---|---|
+87.50% | 10.59M | |
+18.72% | 123B | |
+14.53% | 107B | |
-2.88% | 24.01B | |
+2.18% | 22.59B | |
-10.09% | 18.16B | |
-41.04% | 16.84B | |
-11.83% | 16.23B | |
+1.46% | 13.43B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- BETRF Stock
- News BetterLife Pharma Inc.
- BetterLife Pharma Inc. Advances BETR-001 IND-Enabling Studies